Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. develops sublingual delivery technology designed to deliver drugs and other bioactive substances through rapid absorption under the tongue. Company news commonly covers its drug-delivery platform, applications across active pharmaceutical ingredients, therapeutics, nutraceuticals and supplements, and clinical or regulatory disclosures tied to its development activities.
Updates also include the company’s wholly owned Buzz Bomb Caffeine Company, which markets BUZZ BOMB™ caffeine in single-serving dry powder stick packs for sublingual use. Recurring corporate developments include retail distribution and sales agreements, operating and financial results, shareholder voting matters, governance updates, Nasdaq listing compliance and capital-structure actions such as reverse stock split approvals.
Aspire Biopharma (Nasdaq:ASBP) announced that subsidiary Buzz Bomb Caffeine Company has entered a strategic partnership with EoS Fitness, a high-value, low-price gym chain with more than 225 locations open or planned nationwide.
Through the EoS Flex Deals affiliate program, BUZZ BOMB™ 50mg sublingual caffeine stick packs gain exposure to millions of health-focused members, supported by over 80 million impressions in 2025 via in-gym TV, mobile app offers and on-site demos.
Aspire Biopharma (NASDAQ:ASBP) will effect a one-for-thirty (1:30) reverse stock split of its common stock effective May 11, 2026 at 12:01 AM ET, with post-split trading on Nasdaq under the existing symbol ASBP. The action is intended to bring Aspire into compliance with Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding shares from approximately 36,329,490 to approximately 1,210,983. Outstanding options, warrants, restricted stock awards and equity plan share pools will be adjusted proportionally. No fractional shares will be issued; fractional entitlements will be rounded up to the next whole share.
Aspire Biopharma (NASDAQ:ASBP) announced a Board-authorized $5.0 million share repurchase program to be funded from existing cash on hand. The company also disclosed 2026 milestones: $21M private placements, regained Nasdaq compliance, a Binding LOI to acquire Dura Driver Control Systems for ~$30M, and a commitment letter up to $22.5M to finance the acquisition. Aspire plans to file an NDA for its lead sublingual aspirin candidate near the end of 2026 and reports patents filed on its sublingual delivery technology. BUZZ BOMB consumer brand launched new 50mg sublingual caffeine stick packs and retail partnerships.
Aspire Biopharma (NASDAQ:ASBP) closed the second and final tranche of a private placement, issuing an aggregate of 26,250 Series A convertible preferred shares for total gross proceeds of $21.0 million, before fees.
The company secured a commitment letter for a senior secured credit facility of up to $22.5 million to finance a proposed $30.0 million cash acquisition of Dura Control Systems (DCS), which reported $200M+ revenue and $20M adjusted EBITDA for FY2025 (unaudited). Aspire said stockholders' equity now exceeds the Nasdaq $2.5M listing minimum and that the DCS purchase is not expected to require new equity.
Aspire Biopharma (NASDAQ:ASBP) subsidiary Buzz Bomb Caffeine Company announced that elite ultramarathoner Ashley Paulson will attempt the female world record for the fastest 100-mile treadmill run at the Boston Marathon Expo on April 18, 2026 at the Hynes Convention Center.
Paulson previously set the 100-mile road world record on February 20, 2026 with a time of 12:19:34 and will aim to beat the treadmill mark of 14:15:08. The event will be live and open to spectators, showcasing Buzz Bomb products.
Aspire Biopharma (NASDAQ:ASBP) signed a Letter of Intent on April 16, 2026 to acquire Dura Driver Control Systems (DCS), a global automotive supplier with 100+ year leadership experience. The proposed acquisition would be for $30 million cash, subject to due diligence and a U.S. GAAP audit.
DCS reported $200M+ revenue and $20M+ adjusted EBITDA for FY2025 (unaudited), holds 310 patents across 275 parts, and serves 150+ vehicle platforms. Management additions from Lakewood & Company add collective industry expertise.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company has signed a sales and marketing brokerage agreement with Interwest Brokerage to expand BUZZ BOMB™ retail distribution across Utah, Idaho, and Montana.
The partnership assigns Interwest to lead sales, marketing, and distribution in grocery, convenience, and alternate channels to increase shelf presence and product velocity.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company entered an agreement with TruLife Distribution on March 19, 2026, to manage national sales, distribution, and merchandising of BUZZ BOMB™.
The partnership targets natural, organic, specialty, and mass-merchandiser channels to expand retail footprint for the single‑serve 50mg dry‑powder caffeine stick packs.
Aspire Biopharma (Nasdaq:ASBP) announced on March 17, 2026 that subsidiary Buzz Bomb Caffeine Company appointed John Choe as Western Sales Director. Choe is described as a 25-year industry veteran with prior roles at Yerbaé (2016–2025) and a reported 70% sales increase.
The announcement highlights Choe's experience in retail and beverage distribution, DSD and wholesale relationships, multilingual skills, and his MBA and BS degrees as assets to scale Buzz Bomb's western U.S. sales efforts.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company will feature its flagship product BUZZ BOMB™ at The Health & Fitness Show, March 16-18, 2026 in San Diego.
BUZZ BOMB™ is a 50mg single-serving dry powder stick pack designed to be sprinkled under the tongue for rapid caffeine absorption, portable dosing, and natural flavors with organic, non-GMO caffeine.